Long-Term Response and Remission with Pixantrone in Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma: Post-Hoc Analysis of the Multicenter, Open-Label, Randomized PIX301 Trial

BACKGROUND: Pixantrone is recommended in relapsed and refractory non-Hodgkin lymphoma (NHL) or heavily pretreated NHL patients. Its conditional approval in Europe was based on results from the open-label, randomized, phase 3 PIX301 study, comparing pixantrone monotherapy with physician’s choice of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Pettengell, Ruth, Coiffier, Bertrand, Egorov, Anton, Singer, Jack, Sivcheva, Lilia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5951866/
https://www.ncbi.nlm.nih.gov/pubmed/29564722
http://dx.doi.org/10.1007/s40261-018-0635-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5951866/
https://www.ncbi.nlm.nih.gov/pubmed/29564722
http://dx.doi.org/10.1007/s40261-018-0635-3

Ejemplares similares